Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Shattuck Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
STTK
Nasdaq
2836
www.shattucklabs.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Shattuck Labs, Inc.
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
- Oct 24th, 2024 1:35 pm
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
- Oct 8th, 2024 1:35 pm
Top Midday Decliners
- Oct 2nd, 2024 6:31 pm
Shattuck Labs stock craters following pipeline and job cuts
- Oct 2nd, 2024 3:32 pm
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
- Oct 2nd, 2024 2:21 pm
Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts
- Oct 2nd, 2024 10:57 am
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
- Oct 1st, 2024 4:26 pm
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
- Oct 1st, 2024 10:30 am
Shattuck Labs, Inc. (NASDAQ:STTK) is definitely on the radar of institutional investors who own 43% of the company
- Sep 25th, 2024 2:10 pm
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
- Aug 1st, 2024 10:20 pm
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Aug 1st, 2024 8:05 pm
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
- Jul 30th, 2024 9:00 pm
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
- Jul 12th, 2024 4:55 pm
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
- Jul 10th, 2024 12:10 pm
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
- Jul 1st, 2024 10:00 am
Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK)
- Jun 18th, 2024 10:25 pm
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
- Jun 14th, 2024 5:28 pm
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Jun 14th, 2024 10:00 am
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
- Jun 10th, 2024 11:30 am
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Jun 6th, 2024 11:30 am
Scroll